Cantor Fitzgerald initiates coverage of Lexicon Pharmaceuticals with Overweight rating, $8 price target

Cantor Fitzgerald initiated coverage on Lexicon Pharmaceuticals's stock with a rating of Overweight and a price target of $8.00.The price target implies an upside of 345.7% from the Sep 25 close of $1.79.Key takeaways from the analyst noteStrong Clinical Rationale for HCM Treatment: Lexicon Pharmac…